Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Common Equity: 2013-2024

Historic Common Equity for Zevra Therapeutics (ZVRA) over the last 10 years, with Dec 2024 value amounting to $39.7 million.

  • Zevra Therapeutics' Common Equity rose 90.86% to $133.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.2 million, marking a year-over-year increase of 90.86%. This contributed to the annual value of $39.7 million for FY2024, which is 35.88% down from last year.
  • According to the latest figures from FY2024, Zevra Therapeutics' Common Equity is $39.7 million, which was down 35.88% from $61.9 million recorded in FY2023.
  • Over the past 5 years, Zevra Therapeutics' Common Equity peaked at $127.1 million during FY2021, and registered a low of -$66.4 million during FY2020.
  • Over the past 3 years, Zevra Therapeutics' median Common Equity value was $61.9 million (recorded in 2023), while the average stood at $58.9 million.
  • As far as peak fluctuations go, Zevra Therapeutics' Common Equity spiked by 291.41% in 2021, and later plummeted by 40.91% in 2022.
  • Over the past 5 years, Zevra Therapeutics' Common Equity (Yearly) stood at -$66.4 million in 2020, then surged by 291.41% to $127.1 million in 2021, then plummeted by 40.91% to $75.1 million in 2022, then fell by 17.65% to $61.9 million in 2023, then crashed by 35.88% to $39.7 million in 2024.